Brief: Bellerophon To Present Results From Its Phase 2 iNO-PF Study Of INOpulse® For The Treatment Of Fibrotic Interstitial Lung Disease At Upcoming Scientific Conferences
29/10/2020 13:43
Oct 29 (Reuters) - Bellerophon Therapeutics Inc BLPH.O :
* BELLEROPHON TO PRESENT RESULTS FROM ITS PHASE 2 INO-PF
STUDY OF
INOPULSE® FOR THE TREATMENT OF FIBROTIC INTERSTITIAL LUNG
DISEASE AT UPCOMING SCIENTIFIC CONFERENCES
Source text for Eikon: ID:nGNX8NDrRH
Further company coverage: BLPH.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Bellerophon Therapeutics
See all newsBrief: Bellerophon Therapeutics Inc On October 12, 2023, Board Of Directors Approved Plan Of Liquidation And Dissolution Of Company
Bellerophon Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Bellerophon Therapeutics Inc expected to post a loss of 42 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Archer-Daniels-Midland, Nucor, Copper miners
U.S. STOCKS ON THE MOVE-Hubbell, Spire Global, FibroGen